Conviron and Argus: key players in Medicago’s COVID-19 plant derived vaccine development
Winnipeg-based Conviron, a leading supplier of controlled environments for plant production, is pleased to announce the award of a major project involving the expansion of Medicago’s vaccine manufacturing facilities in Durham NC. Medicago, a biopharmaceutical company headquartered in Quebec City, is moving forward in their participation to the fight against the COVID-19 pandemic by building additional infrastructure for the development and manufacturing of plant-derived vaccines – a process that produces a high volume of vaccine in shorter production timelines.
Located in the Research Triangle Park in North Carolina, the facility expansion features several customized controlled environmental rooms from Conviron, which are used in the manufacturing process for plant germination and plant expression of virus-like particles. Conviron’s sister company amd Indoor Ag-Con 2021 Exhibitor, Argus Controls, is providing the controls and automation of all the plant-growing spaces in the expanded facility. The decision to use Conviron stemmed from the relationship that started back in 2012, when Conviron first provided plant growth rooms to Medicago’s facility in Quebec.
In an interview with Martin Cash (for the Winnipeg Free Press)¹ a spokeswoman for the company said Medicago hopes to have enough data showing the efficacy and safety of the vaccine by the end of June and then would be able to start production shortly after that.
Cash also had to opportunity to review this topic with John Proven, president of Conviron, who said it’s one of the most important projects for Conviron this year. Proven said Conviron is glad to be part of a Canadian effort to battle the pandemic.